Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cognition issues among PLWH

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Oct 11, 2023 9:24am

53 Views

Post# 35678428

RE:RE:RE:Cognition issues among PLWH

But would it not be potentially helpful if a combo trial was initiated on non-HIV patients? Is that market not larger?

scarlet1967 wrote: The clinical trials studying Tesamorelin are including HIV patients and this particular article is about PLWH rather than general population having said that only HIV market is a sizable market and conditions like impaired cognition or peripheral nerve injury are unmet another point is no one can classed them as a cosmetic issue which is the current absolutely incorrect sigma about HIV lipodystrophy.

Mannequin wrote:
Scarlet that is my point. Why is it that we continuously only focus on HIV with it? Is it something specific?

scarlet1967 wrote:
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management | Nature Reviews Neurology

I don't have access to the article but the acknowledgment of the significance of the impaired cognition among PLWH is an important part of the overall HIV patients' so far inadequate medical care process. Egrifta is currently under investigation for that condition which if proven to be part of the solution it will address an unmet medical condition. Point is all these various clinical trials studying the drugs therapeutic effects for conditions such as cardiovascular diseases, impaired cognition and nerve injuries among HIV patients have a untapped commercial market as there more than one million HIV positive patients in the US only.